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About
This policy brief presents the initial findings 
from a company survey carried out in Bang-
ladesh’s pharmaceutical industry as well as 
some policy implications resulting from the 
findings. The survey was undertaken in Jan-
uary 2019, as part of the “Skills for Industry” 
research project. The aim of the research 
project is to understand the contribution of 
vocational skills development (VSD) to inclu-
sive industrial growth and transformation 
in six selected countries in Asia and Africa. 
Data for the survey were collected from 61 
randomly selected pharmaceutical compa-
nies out of 142 listed operational companies 
located in Dhaka city and its surrounding 
areas. Trends in employment, salaries and 
sales volumes are considered as indicators of 
company growth in this study. Similarly, the 
production of advanced products, the adop-
tion of new technologies and the change in 
organizational management indicate trans-
formation.
Background of the Bangladesh Pharmaceutical 
Industry  
The Bangladesh economy has been transforming over 
the past couple of decades, from primarily an agri-
cultural economy, into one with major manufactur-
ing and services sectors. According to the latest data 
from the Bangladesh Bureau of Statistics (BBS), the 
contribution of exports to GDP increased from 5% in 
the fiscal year 1972-1973 to 13.37% in the fiscal year 
2017-18. 
The pharmaceutical sub-sector is one of the most 
technologically advanced and dynamic segments of 
the economy. It re-
corded a cumula-
tive annual growth 
rate (CAGR) of 
21% from 2014 to 
2017. With its cur-
rent contribution 
to GDP of 1.9%, 
this sub-sector is 
relatively small. 
But it is seen 
to be a promis-
ing sub-sector in 
terms of industrial 
growth and trans-
formation. 
Recognising its 
promise, the gov-
ernment applied 
import restrictions 
to encourage lo-
cal manufacturing 
and also to ensure 
drug availability at 
a reasonable price. 
The first National 
Drug Policy was formulated in 1982 with a focus on 
drug safety, quality and price control. 
The policy objectives included promoting Good Man-
ufacturing Practices (GMP) and maintaining a quali-
fied workforce – including pharmacists – in the drug 
manufacturing process. A new drug policy intro-
duced in 2016 further emphasized the employment 
of skilled staff and their regular training to support 
Skills for Industry Policy Brief Bangladesh #1 (2019)
Growth of Bangladesh’s Pharma Industry: 
Some Implications 
Key general findings 
• More than 85% of companies 
have registered growth and 
some form of transformation 
over the last five years, resulting 
in the virtual disappearance of 
small companies in the sub-sec-
tor. 
• Large- and unknown-sized com-
panies reported higher levels 
of transformation than medi-
um-sized companies.
• In the recruitment of workers at 
all levels, from general workers 
to supervisors, most of the com-
panies look at work experience 
rather than VSD certificates. As 
a result, VSD programs are not 
popular or even widely known to 
the job seekers. 
• At the same time,  companies 
in the sub-sector have faced a 
shortage of skilled technicians, 
however, firms rarely provid-
ed in-employment training for 
workers.
GMP in the industry. 
According to the Bangladesh Association of Pharma-
ceutical Industries (BAPI) and the Directorate Gener-
al of Drug Administration (DGDA), there are current-
ly 257 licensed pharmaceutical manufacturers with 
about 150 pharmaceutical units under operation (EBL 
Securities Ltd., 2018). 
Bangladesh is the largest producer of formulated 
drugs among the UN-designated Least Developed 
Countries (LDCs). The quality of the products has 
created a huge demand for Bangladeshi drugs in the 
global market. Bangladesh exports drugs to more 
than 127 countries and meets 97% of the domestic de-
mand. The drug industry’s contribution to the GDP 
has been increasing every year (Islam, Rahman, & Al-
Mahmoon, 2018). 
According to industry analysts, the market size of 
pharmaceuticals may reach about BDT 330,000 mil-
lion by 2020 (EBL Securities Ltd., 2018). However, 
this growth is dependent on fulfilling the industry’s 
demands for a growing number of skilled workers at 
different levels. 
Positive growth and transformation trends
Most of the companies showed a positive change in 
the indicators. More than 90% of companies report-
ed that the number of employees and the volume of 
sales increased by more than 33%. During the last five 
years (2012-17), 92% of companies reported staff sal-
ary increases (at different rates), with 77% reporting 
increases of more than 33%. 
The companies experiencing growth were inclined 
to upgrade their manufacturing processes and pro-
duce more advanced and newer products in order to 
survive in the very competitive global market. To this 
end, they transformed their organizational manage-
ment and adopted new technologies. 
Data show that more than 85% of companies inte-
grated advanced technology into their production 
processes, and produced newer, more advanced prod-
ucts. They also went through organizational chang-
es. On the other hand, around 33% of medium-sized 
companies still struggled across indicators. 
Fast adaptation in both large and unknown- 
sized companies 
More than 85% of companies registered growth 
and some form of transformation over the last five 
years, resulting in the virtual disappearance of small 
companies in the sub-sector. Both the large- and un-
known-sized companies have been very fast in adapt-
ing to change. While small companies are dynamic 
because they need to grow to survive in the compet-
itive market, they seem to adopt a more conservative 
approach once they reach a medium size. The larger 
ones are ambitious and export-oriented. 
Only 38% of companies provided data on the number 
of employees at each level. With a huge 62% of com-
panies withholding employee data, it was difficult to 
accurately chart the range of company sizes. The re-
sult was that in 2017, there was practically no small 
company, according to the survey results. Five years 
earlier, in 2012, 17.4%, 65.2%, and 17.4% companies 
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were small (less than 50 employees), medium (50 to 
249 employees) and large (more than 250 employees) 
respectively.
Data show that large- and unknown sized compa-
nies adjust to produce advanced and newer prod-
ucts, adopt advanced technology and also undertake 
change in operations and management more regular-
ly than medium sized companies. As a consequence, in 
the large and unknown sized companies, recruitment 
rates, salary growth rates and sales are comparatively 
higher. On the other hand, medium-sized companies, 
sticking to a conservative growth strategy, still did 
well in the growth of sales (75%) over the five-year 
period of 2012-17. Their employee growth rates, how-
ever, were lower than for large and unknown sized 
companies. 
Consequences for the supply of skilled workers
The pharmaceutical industry faces difficulties in find-
ing technical employees such as machine operators 
and technicians. Most of the companies do not ex-
press a need for skills training for non-technical em-
ployees – either general workers or their supervisors. 
However, all companies face a skills shortage in tech-
nical personnel, and they assert that VSD programs 
do not meet the industry’s needs. 
In 2017, the average workforce composition was 64% 
general workers, 16% machine operators, 6.5% su-
pervisors, 5% technicians and 8.5% higher manag-
ers. Data also show that 64% of all employees have 
not received any VSD training and 92% of companies 
reported that they did not face difficulties in finding 
general workers. Clearly, the companies do not face a 
shortage of general workers (who do not receive any 
skills training) for non-technical tasks. At the same 
time, 11% of companies reported that they faced dif-
ficulties in finding supervisors, perceiving a minor 
skills shortage for this position. 
It can be reasonably argued that the relatively high 
proportion of employees without VSD training (main-
ly general workers and supervisors) and the require-
ment to compensate for this low skill level of workers 
by investing in equipment might have a major nega-
tive impact on the productivity of the companies. 
Further, companies reported that they faced difficul-
ties in finding technicians (44%), machine operators 
(29%) and higher management staff (25%). These data 
indicate that the pharmaceutical industry has a skills 
shortage in technical jobs at different levels. 
Data show as well that there is a gap in the provision 
of pre-employment training; in other words, gener-
al or lower level technical workers have no training 
before joining the company. Higher managers (84%) 
and technicians (52%) received VSD degrees mainly 
from university before joining.  Only in 25% of com-
panies did operators (10% for supervisors) have pri-
or VSD training. For formal in-employment training, 
on an average, 9.8% of the companies reported that 
they arranged or provided on-the-job training for 
their low-level and mid-level employees. On the other 
hand, 44% companies reported that upper level/man-
agement level employees received further training – 
this includes trainings, which are not conducted by 
the company.
In recruitment of workers at all levels, from general 
workers to technicians, most of the companies look at 
work experience rather than certified qualifications. 
As a result, VSD programs are not popular or even 
widely known to the job seekers. At the same time, 
companies in the sub-sector have faced a shortage of 
skilled technicians.
The overall conclusion regarding VSD is that pre-em-
ployment training is not very popular amongst job 
seekers, and the companies do not demand or see 
much value in existing VSD programs. Industry also 
shows a preference for coping without substantial 
0%
25%
50%
75%
100%
Ge
ne
ra
l w
or
ke
rs
O
pe
ra
to
rs
Te
ch
ni
cia
ns
Su
pe
rv
iso
rs
Hi
gh
er
 m
an
ag
em
en
t
Occupational levels
Pe
rc
en
ta
ge
 o
f c
om
pa
ni
es
Difficulty
not difficult
somewhat difficult
very difficult
Difficulty in hiring employees by level
in-employment training for workers. This situation 
has resulted in relatively low productivity growth 
rates in the industry, even though there has been an 
increase in the volume of production, product vari-
ety, employment numbers, technology adoption and 
salaries.
Policy Implications/Recommendations: 
• Overall, companies in the pharmaceutical 
sub-sector are growing and transforming; how-
ever, medium size companies have not seen as 
much transformation. In this situation, a policy 
objective would be to identify the knowledge and 
success stories of the better-performing compa-
nies and exchange them among stakeholders for 
improving productivity, growth and transforma-
tion. 
• Participation rates of employees (ranging from 
general workers to supervisors) in pre-employ-
ment VSD programs are very limited in this sec-
tor, and in-employment VSD training programs 
are not available to most of the employees. It is 
important to identify reform measures in the 
VSD programs according to the demands of the 
industry so that VSD can make a stronger contri-
bution to the development of companies and the 
industry.
• The industry as a whole and individual companies 
need to pay greater attention to the skills and pro-
ductivity levels of the large proportions of general 
workers and supervisors to raise overall produc-
tivity and to stay competitive in the global mar-
ket. They need to work with VSD providers and 
consider what they can do themselves in terms 
of systematic work-based skills development for 
their workers, including offering apprenticeships 
and internships for future employees.   
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